Supplementary Figures S1-S2 and Supplementary Table S1-S2 from Preclinical Activity of HER2-Selective Tyrosine Kinase Inhibitor Tucatinib as a Single Agent or in Combination with Trastuzumab or Docetaxel in Solid Tumor Models

Abstract

Supplementary Figure S1: Comparative potency of tucatinib, neratinib, and lapatinib in cellular HER2 and EGFR phosphorylation assays; Supplementary Figure S2: Effect of tucatinib, trastuzumab, or combination treatment on mouse body weight in HER2+ PDX models; Supplementary Table S1: Tucatinib activity correlates with HER2 surface receptor density; Supplementary Table S2. HER2 copy number variation in PDX models